TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8677926
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for functional dyspepsia
Study: 1912715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of senna pods and Goleytely solution
Study: 1912715
Drug: Goleytely solution
Normalized name: polyethylene glycol 3350 / potassium chloride / sodium bicarbonate / sodium chloride / sodium sulfate Powder for Oral Solution [Golytely]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goleytely solution (7 litres)
Study: 1912715
Drug: Simethicone (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (additional administration)
Study: 30300800
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone treatment for 12 weeks
Study: 30300800
Drug: Dropped out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dropped out of naltrexone treatment
Study: 21810843
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (statins, antithrombotics, ACEI/ARB)
Study: 18813830
Drug: Cisplatin-paclitaxel (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-paclitaxel (Arm A): Cisplatin 80 mg/m² and paclitaxel 175 mg/m² on day 1, repeated every 3 weeks.
Study: 18813830
Drug: Cisplatin-etoposide (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-etoposide (Arm B): Cisplatin 80 mg/m² on day 1 and etoposide 120 mg/m² per day on days 1-3, repeated every 3 weeks.
Study: 10460524
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol, sufentanil and atracurium
Study: 2797847
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg B.I.D
Study: 788890
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral cyclophosphamide
Study: 30923036
Drug: Anti-PD-1 therapies
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 therapies (nivolumab, pembrolizumab)
Study: 27832248
Drug: Binocular game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Binocular game treatment
Study: 27832248
Drug: Binocular game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Binocular game treatment (after crossover)
Study: 27832248
Drug: Patching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching treatment (after crossover)
Study: 18042304
Drug: Nicotine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (1 mg via nasal spray)
Study: 10372240
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg/day) for 6 months
Study: 10372240
Drug: Glibenclamide (1.25-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (1.25-7.5 mg/day) with diet therapy
Study: 1932613
Drug: Diltiazem (DTZ)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (DTZ) in combination with Propranolol (PPL)
Study: 1932613
Drug: Propranolol (PPL)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PPL) in combination with Diltiazem (DTZ)
Study: 6853404
Drug: Temocillin administered
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin administered intravenously
Study: 23012931
Drug: Intrasite gel
Normalized name: Intrasite Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasite gel (IG group, n = 10)
Study: 23012931
Drug: Intrasite gel
Normalized name: Intrasite Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasite gel (IG group)
Study: 17338899
Drug: Once-daily budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily budesonide (800 microg)
Study: 17338899
Drug: Twice-daily budesonide
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily budesonide (400 microg)
Study: 12234308
Drug: L-arginine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (2.5 g/m(2) or 5 g/m(2) x 3/day)
Study: 9820258
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy and soft tissue therapy
Study: 9820258
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment and soft tissue therapy
Study: 8819662
Drug: Code A
Normalized name: Tricode AR
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Code A (novel time release preparation of ferrous sulphate)
Study: 8819662
Drug: Code B
Normalized name: opacode black
Approvals — FDA: no, EMA: no, PMDA: no
Description: Code B (sustained release ferrous sulphate preparation)
Study: 1663261
Drug: WC3 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC3 rotavirus vaccine (two doses at 1-month interval, first dose at 3 months of age)
Study: 1663261
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses at 1-month interval, first dose at 3 months of age)
Study: 25424299
Drug: Low-intensity pulse
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulse ultrasound stimulation (LIPUS) treatment 15 min/day
Study: 18090188
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (partners of patients with antiarrhythmic drugs and implantable cardioverter defibrillator)
Study: 15347634
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg orally twice daily for 3 days
Study: 15347634
Drug: Trimethoprim/sulfamethoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole 160/800 mg orally twice daily for 7 days
Study: 15347634
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg orally twice daily for 7 days
Study: 9821477
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg o.d. for 4 weeks
Study: 8031419
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg bolus)
Study: 1969244
Drug: Clonazepam treatment
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam treatment
Study: 432800
Drug: Heparin-hydrocortisone combinations
Normalized name: heparin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-hydrocortisone combinations
Study: 23490388
Drug: Telbivudine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine treatment for 4 years
Study: 21232155
Drug: Nicotine-free cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-free cigarettes (Quest 3) for six weeks + NRT patches, gum and/or lozenges for eight weeks
Study: 21232155
Drug: NRT patches,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT patches, gum and/or lozenges for eight weeks
Study: 19597362
Drug: Trauma-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused group therapy
Study: 19597362
Drug: Present-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-focused group therapy
Study: 17191036
Drug: NGF hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NGF hydrocortisone 0.25% cream
Study: 17191036
Drug: NGF hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NGF hydrocortisone 0.5% cream
Study: 17191036
Drug: NGF hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NGF hydrocortisone 1.0% cream
Study: 17191036
Drug: Hydrogalen cream
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogalen cream (hydrocortisone 1.0%)
Study: 17191036
Drug: Hydroderm HC
Normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroderm HC 0.5% cream (hydrocortisone 0.5%)
Study: 17191036
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of test preparations)
Study: 11450886
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime 8 mg/kg/day for 10 days
Study: 11450886
Drug: Initial intramuscular
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intramuscular ceftizoxime 50 mg/kg twice a day for 2 days followed by oral cefixime for 8 days
Study: 9931851
Drug: Adjuvant 3-week
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant 3-week intravenous PGE1 treatment
Study: 8128173
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN), 2.6 mg, administered 2 hours before ingestion of 500 ml meat soup
Study: 8128173
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration (Control)
Study: 2644815
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate (0.6 mg/kg per day in 4 doses for 4 days)
Study: 28121648
Drug: Oral synbiotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral synbiotic (Lactobacillus plantarum and fructo‐oligosaccharides) administered daily for 7 days
Study: 28121648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no synbiotic treatment)
Study: 8123399
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg i.m. 20 min before operation
Study: 24105106
Drug: Triflusal (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (300, 600, 900 mg single doses; 600 mg once daily for 7 days)
Study: 24105106
Drug: Triflusal (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (multiple doses of 600 mg once daily for 7 days)
Study: 24105106
Drug: Triflusal and
Normalized name: triflusal
DrugBank: Triflusal (DB08814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal and HTB (pharmacokinetics)
Study: 23896185
Drug: Flow restrictors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow restrictors (FRs) added to liquid medicine bottles
Study: 6531968
Drug: RA27/3 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA27/3 vaccine strain
Study: 6531968
Drug: BRD‐2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRD‐2 vaccine strain
Study: 30756142
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of anaesthetic solution
Study: 30756142
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml anaesthetic solution
Study: 22773741
Drug: ceftolozane/tazobactam 1.5
Normalized name: ceftolozane/tazobactam 1.5 gram INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftolozane/tazobactam 1.5 g administered every 8 h via a 60 min infusion
Study: 22773741
Drug: piperacillin/tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin/tazobactam 4.5 g administered every 6 h via a 30 min infusion
Study: 20186971
Drug: Relaxing room
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing room therapy
Study: 14557564
Drug: Capsaicin administered
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin administered on day 28
Study: 11039685
Drug: Conjoint Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint Family Therapy (CFT)
Study: 11039685
Drug: Separated Family
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separated Family Therapy (SFT)
Study: 8697144
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (IFN-alpha and IFN-gamma)
Study: 8697144
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) therapy
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lignocaine, 0.5% (L) in rheumatology setting
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml isotonic saline (S) in rheumatology setting
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lignocaine, 0.5% (L) in general practice setting
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml isotonic saline (S) in general practice setting
Study: 6345489
Drug: Chemotherapy adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy adjuvant administered prior to definitive irradiation
Study: 6345489
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity tumors (T3-4 primaries)
Study: 6345489
Drug: N3 nodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: N3 nodes secondary to oral cavity primaries
Study: 2831117
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 to 40 mg/day for 8 weeks)
Study: 23022672
Drug: aripiprazole (3-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: aripiprazole (3-30 mg/day)
Study: 23022672
Drug: perospirone (8-48
Approvals — FDA: no, EMA: no, PMDA: no
Description: perospirone (8-48 mg/day)
Study: 20861007
Drug: Danoprevir (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir (100, 200 mg every 12 h or 8 h for 14 days)
Study: 18456940
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture treatment (AAT) on active points
Study: 18456940
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment (AAT on sham points)
Study: 17135738
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate) for 52 weeks
Study: 17135738
Drug: Alternating group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating group (two-compound product and calcipotriol) for 52 weeks
Study: 17135738
Drug: Calcipotriol for
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol for 48 weeks after 4 weeks of two-compound product
Study: 14564144
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (including ACE inhibitors, diuretics, digoxin)
Study: 10714842
Drug: Diclofenac 2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 2-3 mg kg(‐1) 24 h(‐1)
Study: 10714842
Drug: Acetaminophen 90
Normalized name: acetaminophen 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 90 mg kg(‐1) 24 h(‐1)
Study: 9186890
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH; N = 30)
Study: 9186890
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (N = 14)
Study: 18637604
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg
Study: 26340009
Drug: Scalloped implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalloped implants
Study: 26340009
Drug: Flat implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat implants
Study: 18419482
Drug: Moxifloxacin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin monotherapy (400 mg once per day)
Study: 18419482
Drug: Ceftriaxone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone plus levofloxacin combination therapy
Study: 14656349
Drug: Active sublingual
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sublingual immunotherapy (SLIT) combined with inhaled fluticasone (S+F)
Study: 14656349
Drug: Placebo sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual immunotherapy combined with inhaled fluticasone (placebo S+F)
Study: 10391417
Drug: 4-AP 30
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-AP 30 mg/day
Study: 10391417
Drug: 4-AP 6
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-AP 6 mg/day (active-treatment control)
Study: 1641760
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 10 mg/day
Study: 22062358
Drug: Adalimumab 160
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week
Study: 17129234
Drug: Topical eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eutectic mixture for premature ejaculation (TEMPE)
Study: 3808791
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (WHO-recommended oral rehydration solution) containing Na+ 90 mmol/L
Study: 3808791
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (Pedialyte RS) containing Na+ 75 mmol/L
Study: 27577517
Drug: Dual-energy spectral
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-energy spectral CT with iodixanol (270 mg I/mL)
Study: 27577517
Drug: Conventional high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high iodine contrast agent iohexol (350 mg I/mL)
Study: 23759172
Drug: sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline (50 mg/d)
Study: 15258611
Drug: balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: balanced salt solution
Study: 14512873
Drug: IL-10 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 therapy (SQ IL-10 given daily or thrice weekly)
Study: 10576234
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate plus vaginal misoprostol
Study: 1984534
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate weekly
Study: 1984534
Drug: Chloroquine with
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine with daily proguanil hydrochloride
Study: 1984534
Drug: Mefloquine dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine dosing regimen
Study: 30029896
Drug: 3HP (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP (weekly rifapentine plus isoniazid)
Study: 30029896
Drug: 9H (9-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9H (9-month daily isoniazid)
Study: 26796802
Drug: PEG‐rhG‐CSF 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhG‐CSF 100 μg/kg
Study: 26796802
Drug: rhG‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF 5 μg/kg
Study: 24883322
Drug: AA-PRP injection
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-PRP injection
Study: 22242645
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid ethyl ester formulation 1 (12 g single dose)
Study: 22242645
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid ethyl ester formulation 2 (12 g single dose)
Study: 19840120
Drug: Rimonabant (non-reimbursed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (non-reimbursed diet drug)
Study: 19840120
Drug: Rimonabant (reimbursed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (reimbursed diet drug)
Study: 19840120
Drug: Regular contacts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular contacts with pharmaceutical sales representatives
Study: 17464747
Drug: Test patches
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patches (two types)
Study: 17464747
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control patch (0.9% sodium chloride)
Study: 17464747
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control patch (0.1% sodium lauryl sulphate)
Study: 12141889
Drug: Entacapone therapy
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entacapone therapy
Study: 12141889
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (levodopa)
Study: 356247
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren) 50 mg b.i.d.
Study: 27696551
Drug: Pethidine hydrochloride
Normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine hydrochloride (35 mg) given i.v.
Study: 21820163
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (176 μg/d)
Study: 19438994
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% in a new gel formulation